Zai Lab (ZLAB) Scheduled to Post Quarterly Earnings on Wednesday

Zai Lab (NASDAQ:ZLAB) is scheduled to be announcing its earnings results after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of ($0.83) per share for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

Zai Lab (NASDAQ:ZLAB) last announced its quarterly earnings data on Tuesday, February 27th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($0.11). The firm had revenue of $65.83 million for the quarter, compared to analysts’ expectations of $70.41 million. Zai Lab had a negative net margin of 125.46% and a negative return on equity of 37.07%. On average, analysts expect Zai Lab to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Zai Lab Stock Performance

ZLAB stock opened at $16.25 on Monday. The company has a 50 day moving average price of $17.07 and a two-hundred day moving average price of $22.25. The stock has a market capitalization of $1.61 billion, a P/E ratio of -4.71 and a beta of 1.11. Zai Lab has a one year low of $13.48 and a one year high of $39.50.

Insider Transactions at Zai Lab

In related news, insider Joshua L. Smiley sold 1,988 shares of Zai Lab stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $15.67, for a total value of $31,151.96. Following the completion of the transaction, the insider now directly owns 28,684 shares in the company, valued at $449,478.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, insider Rafael Amado sold 2,544 shares of the company’s stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $18.86, for a total transaction of $47,979.84. Following the sale, the insider now directly owns 20,093 shares of the company’s stock, valued at approximately $378,953.98. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Joshua L. Smiley sold 1,988 shares of the business’s stock in a transaction on Thursday, April 4th. The shares were sold at an average price of $15.67, for a total transaction of $31,151.96. Following the sale, the insider now owns 28,684 shares of the company’s stock, valued at approximately $449,478.28. The disclosure for this sale can be found here. In the last 90 days, insiders sold 12,568 shares of company stock valued at $208,508. Insiders own 5.23% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently commented on ZLAB shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zai Lab in a research report on Friday, January 12th. Citigroup lowered their price target on Zai Lab from $123.00 to $66.00 and set a “buy” rating for the company in a report on Thursday, February 29th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $64.22.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.